{"filings":[{"id":1664236,"accession_number":"0001193125-26-304736","cik":2104204,"company_name":"Alamar Biosciences, Inc.","ticker":"ALMR","form_type":"8-K","filed_at":"2026-07-15T20:04:22+00:00","items":["8.01"],"status":"ready","headline":"Alamar Biosciences announces death of board member Ian Ratcliffe; board size reduced to five","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Independent director Ian Ratcliffe, who served since February 2024, passed away on July 5, 2026.","Board decreased authorized directors from six to five following Mr. Ratcliffe's passing.","Nicholas Naclerio, Ph.D., appointed to the Audit Committee of the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1375827121.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97726,"accession_number":"0001193125-26-213379","cik":2104204,"company_name":"Alamar Biosciences, Inc.","ticker":"ALMR","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alamar Q1 revenue doubled to $26.0M; net loss $21.3M on convertible note remeasurement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $26.0M, +99% YoY; consumable revenue surged 178% to $14.0M.","Gross margin improved to 56% from 49% on manufacturing efficiencies and product mix.","Net loss $21.3M, including $8.6M non-cash loss on convertible notes; operating loss $12.3M.","Cash $69.5M at March 31; after quarter-end IPO raised $197.8M net proceeds.","Launched NULISAseq Neuro 220 Panel and NULISAqpcr AD 5-plex in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":26035000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1375827121.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97725,"accession_number":"0001193125-26-163921","cik":2104204,"company_name":"Alamar Biosciences, Inc.","ticker":"ALMR","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Alamar Biosciences closes IPO of 12.9M shares at $17.00, raising ~$219.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed IPO of 12,937,500 shares of common stock at $17.00 per share, including full exercise of underwriters' option for 1,687,500 shares.","Aggross gross proceeds of approximately $219.9 million before underwriting discounts and offering expenses.","Amended and restated certificate of incorporation and bylaws became effective immediately prior to IPO closing.","Shares now trade on Nasdaq under ticker 'ALMR'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1375827121.5,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}